Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors
- PMID: 22822016
- PMCID: PMC3430951
- DOI: 10.2215/CJN.09620911
Renal dysfunction and elevated blood pressure in long-term childhood cancer survivors
Abstract
Background and objectives: Little is known about renal function and blood pressure (BP) in long-term childhood cancer survivors. This cross-sectional study evaluated prevalence of these outcomes and associated risk factors in long-term childhood cancer survivors at their first visit to a specialized outpatient clinic.
Design, setting, participants, & measurements: Estimated GFR; percentages of patients with albuminuria, hypomagnesemia, and hypophosphatemia; and BP were assessed in 1442 survivors ≥5 years after diagnosis. Multivariable logistic regression analyses were used to estimate effect of chemotherapy, nephrectomy, and radiation therapy on the different outcomes.
Results: At a median age of 19.3 years (interquartile range, 15.6-24.5 years), 28.1% of all survivors had at least one renal adverse effect or elevated BP. The median time since cancer diagnosis was 12.1 years (interquartile range, 7.8-17.5 years). High BP and albuminuria were most prevalent, at 14.8% and 14.5%, respectively. Sixty-two survivors (4.5%) had an estimated GFR <90 ml/min per 1.73 m(2). Survivors who had undergone nephrectomy had the highest risk for diminished renal function (odds ratio, 8.6; 95% confidence interval [CI], 3.4-21.4). Combined radiation therapy and nephrectomy increased the odds of having elevated BP (odds ratio, 4.92; 95% CI, 2.63-9.19), as did male sex, higher body mass index, and longer time since cancer treatment.
Conclusion: Almost 30% of survivors had renal adverse effects or high BP. Therefore, monitoring of renal function in high-risk groups and BP in all survivors may help clinicians detect health problems at an early stage and initiate timely therapy to prevent additional damage.
Figures
References
-
- Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA, EUROCARE Working Group : Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 45: 992–1005, 2009 - PubMed
-
- Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, Jaspers MW, Koning CC, Oldenburger F, Langeveld NE, Hart AA, Bakker PJ, Caron HN, van Leeuwen FE: Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 297: 2705–2715, 2007 - PubMed
-
- Oeffinger KC, Nathan PC, Kremer LC: Challenges after curative treatment for childhood cancer and long-term follow up of survivors. Pediatr Clin North Am 55: 251–273, 2008 - PubMed
-
- Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS, Schwartz CL, Leisenring W, Robison LL, Childhood Cancer Survivor Study : Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355: 1572–1582, 2006 - PubMed
-
- Oberlin O, Fawaz O, Rey A, Niaudet P, Ridola V, Orbach D, Bergeron C, Defachelles AS, Gentet JC, Schmitt C, Rubie H, Munzer M, Plantaz D, Deville A, Minard V, Corradini N, Leverger G, de Vathaire F: Long-term evaluation of Ifosfamide-related nephrotoxicity in children. J Clin Oncol 27: 5350–5355, 2009 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
